Diurnal variations in macrophage phagocytosis 25,26, along with the fact that the response rate of nivolumab depends on the time of administration and aligning ICI administration with the macrophage circadian clock enhances efficacy in tumor-bearing mice 27,28, underscore the role of the macrophage circadian clock in cancer immunotherapy resistance. This evidence concerns the gene CLOCK and cancer.